| Literature DB >> 30526606 |
Edwin Barrios-Villa1, Gerardo Cortés-Cortés1, Patricia Lozano-Zaraín1, Margarita María de la Paz Arenas-Hernández1, Claudia Fabiola Martínez de la Peña1, Ygnacio Martínez-Laguna1, Carmen Torres2, Rosa Del Carmen Rocha-Gracia3.
Abstract
BACKGROUND: The widespread Escherichia coli clone ST131 implicated in multidrug-resistant infections has been recently reported, the majority belonging to O25:H4 serotype and classified into five main virotypes in accordance with the virulence genes carried.Entities:
Keywords: AIEC; Crohn’s disease; IBD; Virotype
Mesh:
Substances:
Year: 2018 PMID: 30526606 PMCID: PMC6287351 DOI: 10.1186/s12941-018-0295-4
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
E. coli ST131 O25:H4/H30-Rx virotypes, according with the virulence genes content.
Modified from Nicolas-Chanoine et al. [11]
| Virotype | Virulence factors encoding genes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||||
| A | + | + | – | ± | – | – | – | – | – | – | – |
| B | – | – | + | ± | – | – | – | – | – | – | – |
| C | – | – | – | + | – | – | – | – | – | – | – |
| D | ± | ± | ± | ± | + | – | ± | ± | ± | ± | ± |
| E | – | – | – | + | – | + | + | + | – | – | – |
| Fa | – | – | + | – | – | + | + | – | – | – | – |
| Ga | – | – | – | + | – | + | – | – | – | – | – |
anew proposed virotype; +, positive PCR result; −, negative PCR result. afa/draBC, Afa/Dr adhesins; afa operon, FM955459; iroN, catecholate siderophore receptor; sat, secreted autotransporter toxin; ibeA, invasion of brain endothelium; papGII, allele II of papG gene; cnf1, cytotoxic necrotizing factor type 1; hlyA, alpha-hemolysin; papGIII, allele III of papG gene; cdtB, cytolethal distending toxin; neuC-K1, K1 variant of group II capsule
Characteristics E. coli CTXR ST131 O25:H4/H30-Rx strains.
Data obtained from Cortés-Cortés et al. [50]
| Strain | β-lactamic Resistance profile | Non-β-lactamic Resistance profile | Genetic resistance determinant | Phylogenetic group | ST/ST complex | AIEC genesa | Virulence genesa |
|---|---|---|---|---|---|---|---|
| C7223 | AMP, AMC, CTX, CAZ | NA, CIP, S, T, TE, SXT | B2 | 4225/131 | |||
| C7225 | AMP, AMC, CTX, CAZ, FEP | NA, CIP, GM, AK, T, TE, | B2 | 131/131 | |||
| C7226 | AMP, AMC, CTX, CAZ, FEP | NA, CIP, GM, AK, T, TE | B2 | 131/131 | |||
| C7230 | AMP, CTX, CAZ, FEP, IMP | NA, CIP, S, GM, T, TE | B2 | 131/131 |
CTX Resistant to cefotaxime, O25:H4/H30-Rx serotype/fimH variant-resistance to fluoroquinolones simultaneously with ESBL CTX-M-15 production, AMP ampicillin, AMC amoxicillin/clavulanic acid, CTX cefotaxime, CAZ ceftazidime, FEP cefepime, IMP imipenem, NA nalidixic acid, CIP ciprofloxacin, AK amikacin, GM gentamicin, T tobramicin, TE tetracycline, SXT sulfamethoxazole trimetoprim, S streptomycin
aThis study
Specific primers used in this study
| Target | Primer name | Sequence 5′ to 3′ | Tm ( °C) | Amplicon size | Reference |
|---|---|---|---|---|---|
| PAI-ICFT073 | RPAi | GGACATCCTGTTACAGCGCGCA | 65 | 925 bp | [ |
| RPAf | TCGCCACCAATCACAGCGAAC | ||||
| PAI-IICFT073 | Cft073.2Ent1 | ATGGATGTTGTATCGCGC | 55 | 400 bp | [ |
| cft073.2Ent2 | ACGAGCATGTGGATCTGC | ||||
| PAI-IJ96 | PapGIf | TCGTGCTCAGGTCCGGAATTT | 57.7 | 400 bp | [ |
| PapGIr | TGGCATCCCACATTATCG | ||||
| PAI-IIJ96 | Hlyd | GGATCCATGAAAACATGGTTAATGGG | 59.3 | 2.3 kb | [ |
| Cnf | GATATTTTTGTTGCCATTGGTTACC | ||||
|
| FimH-F | CACTCAGGGAACCATTCAGGCA | 57 | 975 bp | [ |
| FimH-R | CTTATTGATAAACAAAAGTCAC | ||||
|
| IRON-F | AAGTCAAAGCAGGGGTTGCCCG | 60 | 667 bp | [ |
| IRON-R | GACGCCGACATTAAGACGCAG | ||||
| AFA025-F | GAGTCACGGCAGTCGCGGCGG | 55 | 207 bp | [ | |
| AFA025-R | TTCACCGGCGACCAGCCATCTCC | ||||
|
| Afa-DraF | GGCAGAGGGCCGGCAACAGGC | 60 | 559 bp | [ |
| Afa-DraR | CCCGTAACGCGCCAGCATCTC | ||||
|
| IBEA 10 F | AGGCAGGTGTGCGCCGCGTAC | 60 | 170 bp | [ |
| IBEA 10 R | TGGTGCTCCGGCAAACCATGC | ||||
|
| cnf-f | ATCTTATACTGGATGGGATCATCTTGG | 60 | 974 bp | [ |
| cnf-r | GCAGAACGACGTTCTTCATAAGTAT | ||||
|
| cdtB-f | AACTGATTTTCGCGTTGCGA | 60 | 741 bp | This study |
| cdtB-r | GATACGCCAACAGGGAAATG | ||||
| kpsII-f | GATACGCCAACAGGGAAATG | 63 | 272 bp | [ | |
| kpsII-r | CATCCAGACGATAAGCATGAGCA | ||||
| KI-f | TAGCAAACGTTCTATTGGTGC | 153 bp | |||
|
| insA-f | GGCATCCAACGCCATTCAT | 62 | 178 bp | This study |
| insA-r | TGTCCCTCCTGTTCAGCTACTGA | ||||
|
| insB-f | ATGTTCAGATAATGCCCGATG | 62 | 461 bp | This study |
| insB-r | CGTTGGCCTCAACACGATTT | ||||
|
| vatA1076F | CCTGGGACATAATGGTCAGAT | 61 | 330 bp | Arenas-Hernández unpublished data |
| vatA1406R | CTGGCAATATTCACGCTACTG | ||||
|
| vatP-86F | TAGCGCGCAATTCAACAATA | 61 | 226 bp | Arenas-Hernández unpublished data |
| vatP226R | GCAGATAGTGCCAGAGAGGTAAG | ||||
|
| IntI1-F | GGGTCAAGGATCTGGATTTCG | 62 | 483 bp | [ |
| IntI1-R | CGACGATGATTTACACGCATGT | ||||
|
| papA-45F | CAGATATCTCGGTGTGTTCAGTAA | 61 | 641 bp | Arenas-Hernández unpublished data |
| papA + 31R | GGTCTTGCCTCACCCTGTAA | ||||
|
| ihaEMSAR | CGGAATTCCGATCTCCGATCATGTTAACCG | 61 | 150 bp | [ |
| ihaEMSAL | CGGAATTCCGGCATGCCGAGGCAGTCGTTA | ||||
|
| iucD-30F | GCTGTGGCTGGTAACTCAGG | 58 | 512 bp | Arenas-Hernández unpublished data |
| iucD512R | TGCTTCACACAGGGTGGTAAAT | ||||
|
| FliC 242F | GCTGTCCGAAATCAACAACAA | 58 | 304 bp | Arenas-Hernández unpublished data |
| FliC 445 R | GGCTATCGTACCGGAACCATT | ||||
| Fimbrial adhesin subunit | TGACTGTGACCGAAGAGTGC | 48 | 380 bp | [ | |
| TTAGTTCGTCCAGTAACCCCC | |||||
| IS3 Transposase family | STI-F | TTAATAGCACCCGGTACAAGCAGG | 64 | 147 bp | [ |
| STI-R | CTTGACTTCTTCAAAAGAGAAAATTAC | ||||
| Heat-stable enterotoxin | STaII-F | TTGTCTTTTTCACCTTTCCC | 60 | 93 bp | [ |
| STaII-R | ACAAGCAGGATTACAACACA | ||||
| Heat-labile enterotoxin | LT-F | GGCGACAGATTATACCGTGC | 60 | 750 bp | [ |
| LT-R | CCGAATTCTGTTATAATATGTC | ||||
| Intimin | CAGGTCGTCGTGTCTGCTAAA | 67 | 1087 bp | [ | |
| TCAGCGTGGTTGGATCAACCT | |||||
| Shiga toxin 1 | STx1-F | TTTACGATAGACTTCTCGAC | 55 | 227 bp | [ |
| STx2-R | CACATATAAATTATTTCGCTC | ||||
| Shiga toxin 2 | STx2-F | CCCAGTCACGACGTTGTA | 60 | 460 bp | [ |
| STx2-R | TATACTATCGTGCCTTTCCA | ||||
|
| ial-F | CTGGATGGTATGGTGAGG | 60 | 320 bp | [ |
| ial-R | GGAGGCCAACAATTATTTCC | ||||
|
| EAF-F | CAGGGTAAAAGAAAGATGATAA | 58 | 1087 bp | [ |
| EAF-R | TATGGGGACCATGTATTATCA | ||||
|
| AATGGTGCTTGCGCTTGCTGC | 67 | 326 bp | [ | |
| GCCGCTTTATCCAACCTGGTA | |||||
| EAEC plasmid | EAEC-F | CTGGCGAAAGACTGTATCAT | 60 | 630 bp | [ |
| EAEC-R | CAATGTATAGAAATCGCTGTT |
Fig. 1Adherence patterns observed in E. coli ST131 O25:H4/H30-Rx strains. A E. coli K-12, B UPEC CFT073, C C7223, D C7225, E C7226, F C7230. All strains were triple tested and stained with Giemsa
Fig. 2Adherence (a) and invasion (b) assays for the E. coli ST131 O25:H4/H30-Rx strains. All strains were triple tested. An * shows significant differences
Fig. 3Survival within macrophages and Biofilm formation. E. coli ST131 O25:H4/H30-Rx within J774 macrophages (a), all strains were triple tested, and biofilm formation assay (b), all strains were tested eight times. An * shows significant differences
Characterization of E. coli ST131 O25:H4/H30-Rx strains with traits of the AIEC pathotype
| Strain | Adherence ratea | Invasion rateb | Survival within macrophagesc | Biofilm formation rated |
|---|---|---|---|---|
| C7223 | 60.4 b/c | 1.8 × 102 | 3.3 × 102 | 48.13 |
| C7225 | 17.3 b/c | 1.2 × 108 | 2.3 × 105 | 51.44 |
| C7236 | 18.9 b/c | 1.4 × 108 | 2.0 × 105 | 46.9 |
| C7230 | 12.6 b/c | 3.2 × 104 | 4.4 × 103 | 46.47 |
Determination of E. coli strains as belonging to the AIEC pathotype was performed using the following criteria: (1) the ability to adhere to HeLa cells with an adhesion index equal or superior to 1 bacteria per cell (b/c), (2) the ability of the bacteria to invade HeLa cells with an invasion index equal or superior to 0.1% of the original inoculum, (3) the ability to survive and to replicate within J774 macrophages
aAdherence rate is expressed as the mean of bacteria adhered to one HeLa cell
bInvasion is the mean CFUs after 1 h rifampicin treatment of infected HeLa cells
cMean of intracellular bacteria at 3 h post infection relative to the number after 1 h rifampicin treatment, defined as 100% (MOI of 100)
dBiofilm formation rate is defined as milligrams per grams of total protein